Which has preferable earnings and valuation, ALVO or LYEL?

Alvotech has higher revenue and earnings than Lyell Immunopharma. Alvotech is trading at a lower price-to-earnings ratio than Lyell Immunopharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Alvotech $588.90M 1.88 $27.92M -$0.25 N/A Lyell Immunopharma $40K 7,047.99 -$274.45M -$13.80 N/A

Does the media refer more to ALVO or LYEL?

In the previous week, Alvotech and Alvotech both had 3 articles in the media. Alvotech's average media sentiment score of 1.29 beat Lyell Immunopharma's score of 0.47 indicating that Alvotech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alvotech 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lyell Immunopharma 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer LYEL or COLL?

In the previous week, Lyell Immunopharma had 1 more articles in the media than Collegium Pharmaceutical. MarketBeat recorded 3 mentions for Lyell Immunopharma and 2 mentions for Collegium Pharmaceutical. Collegium Pharmaceutical's average media sentiment score of 0.96 beat Lyell Immunopharma's score of 0.47 indicating that Collegium Pharmaceutical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lyell Immunopharma 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Collegium Pharmaceutical 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor LYEL or CGEM?

In the previous week, Lyell Immunopharma and Lyell Immunopharma both had 3 articles in the media. Cullinan Therapeutics' average media sentiment score of 0.60 beat Lyell Immunopharma's score of 0.47 indicating that Cullinan Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lyell Immunopharma 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cullinan Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation and earnings, MGTX or LYEL?

MeiraGTx has higher revenue and earnings than Lyell Immunopharma. MeiraGTx is trading at a lower price-to-earnings ratio than Lyell Immunopharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MeiraGTx $79.76M 14.28 -$114.20M -$1.48 N/A Lyell Immunopharma $40K 7,047.99 -$274.45M -$13.80 N/A

Does the media prefer MGTX or LYEL?

In the previous week, MeiraGTx had 1 more articles in the media than Lyell Immunopharma. MarketBeat recorded 4 mentions for MeiraGTx and 3 mentions for Lyell Immunopharma. MeiraGTx's average media sentiment score of 1.14 beat Lyell Immunopharma's score of 0.47 indicating that MeiraGTx is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MeiraGTx 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lyell Immunopharma 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer CRVS or LYEL?

In the previous week, Lyell Immunopharma had 1 more articles in the media than Corvus Pharmaceuticals. MarketBeat recorded 3 mentions for Lyell Immunopharma and 2 mentions for Corvus Pharmaceuticals. Corvus Pharmaceuticals' average media sentiment score of 1.66 beat Lyell Immunopharma's score of 0.47 indicating that Corvus Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Corvus Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Lyell Immunopharma 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Lyell Immunopharma (LYEL) Competitors

$12.08 +0.47 (+4.08%)

As of 09:40 AM Eastern

Compare

LYEL vs. ALVO, COLL, CGEM, MGTX, and CRVS

Should you buy Lyell Immunopharma stock or one of its competitors? MarketBeat compares Lyell Immunopharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Lyell Immunopharma include Alvotech (ALVO), Collegium Pharmaceutical (COLL), Cullinan Therapeutics (CGEM), MeiraGTx (MGTX), and Corvus Pharmaceuticals (CRVS). These companies are all part of the "pharmaceutical products" industry.

How does Lyell Immunopharma compare to Alvotech?

Alvotech (NASDAQ:ALVO) and Lyell Immunopharma (NASDAQ:LYEL) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, earnings, media sentiment, profitability, institutional ownership and dividends.

Alvotech has higher revenue and earnings than Lyell Immunopharma. Alvotech is trading at a lower price-to-earnings ratio than Lyell Immunopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alvotech	$588.90M	1.88	$27.92M	-$0.25	N/A
Lyell Immunopharma	$40K	7,047.99	-$274.45M	-$13.80	N/A

In the previous week, Alvotech and Alvotech both had 3 articles in the media. Alvotech's average media sentiment score of 1.29 beat Lyell Immunopharma's score of 0.47 indicating that Alvotech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alvotech	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lyell Immunopharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Alvotech currently has a consensus price target of $7.60, indicating a potential upside of 107.37%. Lyell Immunopharma has a consensus price target of $43.00, indicating a potential upside of 255.84%. Given Lyell Immunopharma's stronger consensus rating and higher possible upside, analysts plainly believe Lyell Immunopharma is more favorable than Alvotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alvotech	2 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00
Lyell Immunopharma	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

66.1% of Lyell Immunopharma shares are held by institutional investors. 6.2% of Lyell Immunopharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Alvotech has a net margin of -14.36% compared to Lyell Immunopharma's net margin of -794,858.12%. Alvotech's return on equity of -11.92% beat Lyell Immunopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alvotech	-14.36%	-11.92%	-7.59%
Lyell Immunopharma	-794,858.12%	-85.71%	-66.41%

Alvotech has a beta of 0.21, indicating that its stock price is 79% less volatile than the broader market. Comparatively, Lyell Immunopharma has a beta of -0.09, indicating that its stock price is 109% less volatile than the broader market.

Summary

Alvotech and Lyell Immunopharma tied by winning 8 of the 16 factors compared between the two stocks.

How does Lyell Immunopharma compare to Collegium Pharmaceutical?

Lyell Immunopharma (NASDAQ:LYEL) and Collegium Pharmaceutical (NASDAQ:COLL) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, earnings, valuation, media sentiment, profitability and analyst recommendations.

Collegium Pharmaceutical has higher revenue and earnings than Lyell Immunopharma. Lyell Immunopharma is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lyell Immunopharma	$40K	7,047.99	-$274.45M	-$13.80	N/A
Collegium Pharmaceutical	$796.33M	1.47	$62.87M	$2.04	17.72

Lyell Immunopharma presently has a consensus price target of $43.00, suggesting a potential upside of 255.84%. Collegium Pharmaceutical has a consensus price target of $57.50, suggesting a potential upside of 59.09%. Given Lyell Immunopharma's higher probable upside, research analysts clearly believe Lyell Immunopharma is more favorable than Collegium Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lyell Immunopharma	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Collegium Pharmaceutical	0 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.83

66.1% of Lyell Immunopharma shares are held by institutional investors. 6.2% of Lyell Immunopharma shares are held by insiders. Comparatively, 1.9% of Collegium Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Collegium Pharmaceutical has a net margin of 9.41% compared to Lyell Immunopharma's net margin of -794,858.12%. Collegium Pharmaceutical's return on equity of 95.18% beat Lyell Immunopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lyell Immunopharma	-794,858.12%	-85.71%	-66.41%
Collegium Pharmaceutical	9.41%	95.18%	16.39%

Lyell Immunopharma has a beta of -0.09, indicating that its share price is 109% less volatile than the broader market. Comparatively, Collegium Pharmaceutical has a beta of 0.75, indicating that its share price is 25% less volatile than the broader market.

In the previous week, Lyell Immunopharma had 1 more articles in the media than Collegium Pharmaceutical. MarketBeat recorded 3 mentions for Lyell Immunopharma and 2 mentions for Collegium Pharmaceutical. Collegium Pharmaceutical's average media sentiment score of 0.96 beat Lyell Immunopharma's score of 0.47 indicating that Collegium Pharmaceutical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lyell Immunopharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Collegium Pharmaceutical	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Collegium Pharmaceutical beats Lyell Immunopharma on 10 of the 16 factors compared between the two stocks.

How does Lyell Immunopharma compare to Cullinan Therapeutics?

Lyell Immunopharma (NASDAQ:LYEL) and Cullinan Therapeutics (NASDAQ:CGEM) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, institutional ownership, dividends, analyst recommendations, risk and earnings.

66.1% of Lyell Immunopharma shares are held by institutional investors. Comparatively, 86.3% of Cullinan Therapeutics shares are held by institutional investors. 6.2% of Lyell Immunopharma shares are held by insiders. Comparatively, 8.6% of Cullinan Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Lyell Immunopharma and Lyell Immunopharma both had 3 articles in the media. Cullinan Therapeutics' average media sentiment score of 0.60 beat Lyell Immunopharma's score of 0.47 indicating that Cullinan Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lyell Immunopharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cullinan Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cullinan Therapeutics has lower revenue, but higher earnings than Lyell Immunopharma. Cullinan Therapeutics is trading at a lower price-to-earnings ratio than Lyell Immunopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lyell Immunopharma	$40K	7,047.99	-$274.45M	-$13.80	N/A
Cullinan Therapeutics	N/A	N/A	-$219.88M	-$3.36	N/A

Lyell Immunopharma presently has a consensus target price of $43.00, suggesting a potential upside of 255.84%. Cullinan Therapeutics has a consensus target price of $32.00, suggesting a potential upside of 70.27%. Given Lyell Immunopharma's stronger consensus rating and higher possible upside, research analysts plainly believe Lyell Immunopharma is more favorable than Cullinan Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lyell Immunopharma	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Cullinan Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Cullinan Therapeutics has a net margin of 0.00% compared to Lyell Immunopharma's net margin of -794,858.12%. Cullinan Therapeutics' return on equity of -51.45% beat Lyell Immunopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lyell Immunopharma	-794,858.12%	-85.71%	-66.41%
Cullinan Therapeutics	N/A	-51.45%	-47.64%

Lyell Immunopharma has a beta of -0.09, suggesting that its share price is 109% less volatile than the broader market. Comparatively, Cullinan Therapeutics has a beta of -0.01, suggesting that its share price is 101% less volatile than the broader market.

Summary

Cullinan Therapeutics beats Lyell Immunopharma on 10 of the 15 factors compared between the two stocks.

How does Lyell Immunopharma compare to MeiraGTx?

MeiraGTx (NASDAQ:MGTX) and Lyell Immunopharma (NASDAQ:LYEL) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, media sentiment, risk, earnings and valuation.

In the previous week, MeiraGTx had 1 more articles in the media than Lyell Immunopharma. MarketBeat recorded 4 mentions for MeiraGTx and 3 mentions for Lyell Immunopharma. MeiraGTx's average media sentiment score of 1.14 beat Lyell Immunopharma's score of 0.47 indicating that MeiraGTx is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MeiraGTx	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lyell Immunopharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

MeiraGTx has a beta of 1.26, meaning that its stock price is 26% more volatile than the broader market. Comparatively, Lyell Immunopharma has a beta of -0.09, meaning that its stock price is 109% less volatile than the broader market.

MeiraGTx has higher revenue and earnings than Lyell Immunopharma. MeiraGTx is trading at a lower price-to-earnings ratio than Lyell Immunopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MeiraGTx	$79.76M	14.28	-$114.20M	-$1.48	N/A
Lyell Immunopharma	$40K	7,047.99	-$274.45M	-$13.80	N/A

67.5% of MeiraGTx shares are held by institutional investors. Comparatively, 66.1% of Lyell Immunopharma shares are held by institutional investors. 7.4% of MeiraGTx shares are held by insiders. Comparatively, 6.2% of Lyell Immunopharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

MeiraGTx has a net margin of -151.12% compared to Lyell Immunopharma's net margin of -794,858.12%. Lyell Immunopharma's return on equity of -85.71% beat MeiraGTx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MeiraGTx	-151.12%	-1,065.47%	-54.96%
Lyell Immunopharma	-794,858.12%	-85.71%	-66.41%

MeiraGTx presently has a consensus price target of $25.83, indicating a potential upside of 110.10%. Lyell Immunopharma has a consensus price target of $43.00, indicating a potential upside of 255.84%. Given Lyell Immunopharma's higher probable upside, analysts clearly believe Lyell Immunopharma is more favorable than MeiraGTx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MeiraGTx	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Lyell Immunopharma	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

Summary

MeiraGTx beats Lyell Immunopharma on 12 of the 16 factors compared between the two stocks.

How does Lyell Immunopharma compare to Corvus Pharmaceuticals?

Corvus Pharmaceuticals (NASDAQ:CRVS) and Lyell Immunopharma (NASDAQ:LYEL) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, valuation, risk, institutional ownership, analyst recommendations and earnings.

Corvus Pharmaceuticals currently has a consensus target price of $33.33, suggesting a potential upside of 141.62%. Lyell Immunopharma has a consensus target price of $43.00, suggesting a potential upside of 255.84%. Given Lyell Immunopharma's higher probable upside, analysts plainly believe Lyell Immunopharma is more favorable than Corvus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Corvus Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Lyell Immunopharma	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

Corvus Pharmaceuticals has a net margin of 0.00% compared to Lyell Immunopharma's net margin of -794,858.12%. Corvus Pharmaceuticals' return on equity of -38.92% beat Lyell Immunopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Corvus Pharmaceuticals	N/A	-38.92%	-35.75%
Lyell Immunopharma	-794,858.12%	-85.71%	-66.41%

In the previous week, Lyell Immunopharma had 1 more articles in the media than Corvus Pharmaceuticals. MarketBeat recorded 3 mentions for Lyell Immunopharma and 2 mentions for Corvus Pharmaceuticals. Corvus Pharmaceuticals' average media sentiment score of 1.66 beat Lyell Immunopharma's score of 0.47 indicating that Corvus Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Corvus Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Lyell Immunopharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Corvus Pharmaceuticals has a beta of 0.84, meaning that its stock price is 16% less volatile than the broader market. Comparatively, Lyell Immunopharma has a beta of -0.09, meaning that its stock price is 109% less volatile than the broader market.

Corvus Pharmaceuticals has higher earnings, but lower revenue than Lyell Immunopharma. Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than Lyell Immunopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Corvus Pharmaceuticals	N/A	N/A	-$15.28M	-$0.52	N/A
Lyell Immunopharma	$40K	7,047.99	-$274.45M	-$13.80	N/A

46.6% of Corvus Pharmaceuticals shares are held by institutional investors. Comparatively, 66.1% of Lyell Immunopharma shares are held by institutional investors. 19.7% of Corvus Pharmaceuticals shares are held by company insiders. Comparatively, 6.2% of Lyell Immunopharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Corvus Pharmaceuticals beats Lyell Immunopharma on 9 of the 15 factors compared between the two stocks.

Get Lyell Immunopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LYEL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LYEL vs. The Competition

Export

Metric	Lyell Immunopharma	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$284.51M	$3.02B	$6.83B	$12.17B
Dividend Yield	N/A	1.87%	2.66%	6.11%
P/E Ratio	-0.88	19.54	25.88	24.17
Price / Sales	7,047.99	328.22	550.12	99.13
Price / Cash	N/A	56.85	29.09	36.93
Price / Book	1.03	4.21	10.76	6.38
Net Income	-$274.45M	$64.45M	$3.58B	$337.00M
7 Day Performance	0.95%	1.32%	1.93%	-0.23%
1 Month Performance	-30.27%	-1.07%	-0.23%	-1.40%
1 Year Performance	35.17%	29.70%	34.40%	27.76%

Lyell Immunopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LYEL Lyell Immunopharma	3.8011 of 5 stars	$12.08 +4.1%	$43.00 +255.8%	+29.9%	$284.51M	$40K	N/A	270	High Trading Volume
ALVO Alvotech	4.0898 of 5 stars	$3.70 +1.4%	$7.60 +105.4%	-59.7%	$1.10B	$588.90M	N/A	1,460
COLL Collegium Pharmaceutical	2.6649 of 5 stars	$34.62 +3.5%	$57.50 +66.1%	+22.3%	$1.08B	$780.57M	16.97	210	Positive News
CGEM Cullinan Therapeutics	2.6906 of 5 stars	$17.75 +2.6%	$32.00 +80.3%	+137.1%	$1.06B	N/A	N/A	30
MGTX MeiraGTx	2.8452 of 5 stars	$11.81 +2.9%	$25.83 +118.7%	+82.8%	$1.06B	$81.39M	N/A	300

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LYEL) was last updated on 6/29/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Lyell Immunopharma (LYEL) Competitors

LYEL vs. ALVO, COLL, CGEM, MGTX, and CRVS

How does Lyell Immunopharma compare to Alvotech?

Summary

How does Lyell Immunopharma compare to Collegium Pharmaceutical?

Summary

How does Lyell Immunopharma compare to Cullinan Therapeutics?

Summary

How does Lyell Immunopharma compare to MeiraGTx?

Summary

How does Lyell Immunopharma compare to Corvus Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LYEL vs. The Competition

Lyell Immunopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Lyell Immunopharma (LYEL) Competitors

LYEL vs. ALVO, COLL, CGEM, MGTX, and CRVS

How does Lyell Immunopharma compare to Alvotech?

Which has preferable earnings and valuation, ALVO or LYEL?

Does the media refer more to ALVO or LYEL?

Do analysts prefer ALVO or LYEL?

Do insiders and institutionals have more ownership in ALVO or LYEL?

Is ALVO or LYEL more profitable?

Which has more risk and volatility, ALVO or LYEL?

Summary

How does Lyell Immunopharma compare to Collegium Pharmaceutical?

Which has better earnings and valuation, LYEL or COLL?

Do analysts rate LYEL or COLL?

Do institutionals & insiders believe in LYEL or COLL?

Is LYEL or COLL more profitable?

Which has more risk and volatility, LYEL or COLL?

Does the media prefer LYEL or COLL?

Summary

How does Lyell Immunopharma compare to Cullinan Therapeutics?

Do insiders and institutionals hold more shares of LYEL or CGEM?

Does the media favor LYEL or CGEM?

Which has better valuation and earnings, LYEL or CGEM?

Do analysts prefer LYEL or CGEM?

Is LYEL or CGEM more profitable?

Which has more volatility and risk, LYEL or CGEM?

Summary

How does Lyell Immunopharma compare to MeiraGTx?

Does the media prefer MGTX or LYEL?

Which has more risk & volatility, MGTX or LYEL?

Which has better valuation and earnings, MGTX or LYEL?

Do institutionals and insiders believe in MGTX or LYEL?

Is MGTX or LYEL more profitable?

Do analysts rate MGTX or LYEL?

Summary

How does Lyell Immunopharma compare to Corvus Pharmaceuticals?

Do analysts rate CRVS or LYEL?

Is CRVS or LYEL more profitable?

Does the media prefer CRVS or LYEL?

Which has more risk & volatility, CRVS or LYEL?

Which has stronger earnings & valuation, CRVS or LYEL?

Do institutionals and insiders have more ownership in CRVS or LYEL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LYEL vs. The Competition

Lyell Immunopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools